Quantitative EEG effects of carbamazepine, oxcarbazepine, valproate, lamotrigine, and possible clinical relevance of the findings

被引:62
作者
Clemens, Bela
Menes, Andrea
Piros, Palma
Bessenyei, Monika
Altmann, Anna
Jerney, Judit
Kollar, Katalin
Rosdy, Beata
Rozsavolgyi, Margit
Steinecker, Katalin
Hollody, Katalin
机构
[1] Kenezy Gyula Mem Hosp, Dept Neurol, Epilepsy Ctr, H-4031 Debrecen, Hungary
[2] Kenezy Gyula Mem Hosp, Dept Child Neurol & Psychiat, H-4031 Debrecen, Hungary
[3] Budai Childrens Hosp, Epilepsy Ctr, Budapest, Hungary
[4] Heim Pal Childrens Hosp, Budapest, Hungary
[5] Cent Mil Hosp, Dept Neurol, Budapest, Hungary
[6] Cty Hosp Veszprem, Dept Neurol, Veszprem, Hungary
[7] Univ Pecs, Dept Pediat, Pecs, Hungary
关键词
quantitative EEG; neurotoxicity; cognitive impairment; carbamazepine; valproate; lamotrigine; oxcarbazepine;
D O I
10.1016/j.eplepsyres.2006.05.003
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Quantitative EEG (QEEG) effects of therapeutic doses of carbamazepine (CBZ), oxcarbazepine (OXC), valproate (VA) and lamotrigine (LA) monotherapy were investigated in patients with beginning epilepsy. Baseline waking EEG (EEG 1) was recorded in the untreated state, the second EEG (EEG2) was done after 8 weeks of reaching the therapeutic dose. Left occipital data were used for analysis. QEEG target parameters were absolute band-power (delta: AD, theta: AT, alpha: AA, beta: AB), and alpha mean frequency (AMF). Group effects (untreated versus treated condition in the CBZ, VA, OXC, LA groups) were computed for each target parameter. One group with benign rolandic epilepsy remained untreated for clinical reasons and served to estimate the QEEG test-retest differences. In addition, the individual QEEG response to each drug was calculated as (EEG2-EEG1). Results: statistically significant (p < 0.05) group differences indicated the QEEG domain systematically affected by the drugs. CBZ caused AT increase and AMF decrease. OXC caused AMF decrease. VA and LA did not decrease AMF (LA even increased it), but reduced broad-band power. Individual power and AMF changes showed considerable variability in each group. > 0.5 Hz AMF decrease (that was reported to predict cognitive impairment in prior studies) occurred in 10/41 patients in the CBZ group but never in the OXC, VA, LA groups. The results may be utilized in planning further studies addressing the relationship between antiepileptic drugs and their CNS effects. In addition, the relationship of AED-related cognitive impairment and AMF changes was discussed. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:190 / 199
页数:10
相关论文
共 37 条
[1]   Effects of antiepileptic drugs on cognition [J].
Aldenkamp, AP .
EPILEPSIA, 2001, 42 :46-49
[2]   Randomized double-blind parallel-group study comparing cognitive effects of a low-dose lamotrigine with valproate and placebo in healthy volunteers [J].
Aldenkamp, AP ;
Arends, J ;
Bootsma, HPR ;
Diepman, L ;
Hulsman, J ;
Lambrechts, D ;
Leenen, L ;
Majoie, M ;
Schellekens, A ;
de Vocht, J .
EPILEPSIA, 2002, 43 (01) :19-26
[3]   PREDICTIVE FACTORS OF SEIZURE FREQUENCY AND DURATION OF ANTIEPILEPTIC TREATMENT IN ROLANDIC EPILEPSY - A RETROSPECTIVE STUDY [J].
AMBROSETTO, G ;
ROSSI, PG ;
TASSINARI, CA .
BRAIN & DEVELOPMENT, 1987, 9 (03) :300-304
[4]   Peak alpha frequency: an electroencephalographic measure of cognitive preparedness [J].
Angelakis, E ;
Lubar, JF ;
Stathopoulou, S ;
Kounios, J .
CLINICAL NEUROPHYSIOLOGY, 2004, 115 (04) :887-897
[5]   PROPOSAL FOR REVISED CLASSIFICATION OF EPILEPSIES AND EPILEPTIC SYNDROMES [J].
不详 .
EPILEPSIA, 1989, 30 (04) :389-399
[6]  
Basar E., 1999, BRAIN FUNCTION OSCIL, VII, P393
[7]   EEG CHANGES IN PATIENTS DURING THE INTRODUCTION OF CARBAMAZEPINE [J].
BESSER, R ;
HORNUNG, K ;
THEISOHN, M ;
ROTHACHER, G ;
KRAMER, G .
ELECTROENCEPHALOGRAPHY AND CLINICAL NEUROPHYSIOLOGY, 1992, 83 (01) :19-23
[8]   Objective assessment of neurotoxicity while shifting from carbamazepine to oxcarbazepine [J].
Clemens, B ;
Ménes, A ;
Nagy, Z .
ACTA NEUROLOGICA SCANDINAVICA, 2004, 109 (05) :324-329
[9]  
CLEMENS B, 1999, CLIN NEUROSCI IDEGGY, V52, P307
[10]  
CLEMENS B, 2003, CLIN NEUROSCI, V56, P92